Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CTLA-4

CTLA-4

Brief Information

Name:Cytotoxic T-Lymphocyte-Associated Antigen 4
Target Synonym:Celiac Disease 3,Ligand And Transmembrane Spliced Cytotoxic T Lymphocyte Associated Antigen 4,Cytotoxic T-Lymphocyte Protein 4,CD152,Cytotoxic T-lymphocyte-associated antigen 4,CTLA4,CTLA-4,Cytotoxic T-Lymphocyte Associated Protein 4,Insulin-Dependent Diabetes Mellitus 12,Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Form,Cytotoxic T-Lymphocyte-Associated Serine Esterase-4,CD152 Isoform,CD152 Antigen,CELIAC3,IDDM12,ALPS5,GRD4,GSE,CD,CTLA-4 Antigen
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:48
Lastest Research Phase:Approved

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
CT4-R52H6 Rat Rat CTLA-4 / CD152 Protein, His Tag
CT4-R52H6-structure
CT4-R52H6-sds
CT4-R52H4 Rabbit Rabbit CTLA-4 / CD152 Protein, His Tag
CT4-R52H4-structure
EP-117 Human B7-2 [Biotinylated] : CTLA-4 Inhibitor Screening ELISA Kit
EP-125 Human CTLA-4 [Biotinylated] : B7-1 Inhibitor Screening ELISA Kit
EP-126 Human CTLA-4 [Biotinylated] : B7-2 Inhibitor Screening ELISA Kit
EP-116 Human B7-1 [Biotinylated] : CTLA-4 Inhibitor Screening ELISA Kit
MBS-K042 Human Human CTLA-4 coupled Magnetic Beads
CT4-H82A3 Human Biotinylated Human CTLA-4 Protein, Mouse IgG2a Fc,Avitag™
CT4-H82A3-structure
CT4-H82A3-sds
CT4-H52H9 Human Human CTLA-4 / CD152 Protein, His Tag, active dimer (MALS verified)
CT4-H52H9-sds
CT4-H82E3 Human Biotinylated Human CTLA-4 Protein, His,Avitag™ (MALS verified)
CT4-H82E3-structure
CT4-H82E3-sds
CT4-M82E7 Mouse Biotinylated Mouse CTLA-4 Protein, His,Avitag™
CT4-M82E7-structure
CT4-M82E7-sds
ECH-V1 Human ELISA Assay Kit for Anti-CTLA-4 h-mAb in Human Serum
ECC-V1 Monkey ELISA Assay Kit for Anti-CTLA-4 h-mAb in Monkey Serum
ECM-V1 Mouse ELISA Assay Kit for Anti-CTLA-4 h-mAb in Mouse Serum
CT4-H82E1 Human Biotinylated Human CTLA-4 Protein, His,Avitag™
CT4-H82E1-structure
CT4-H82E1-sds
CT4-H52A4 Human Human CTLA-4 / CD152 Protein, mouse IgG2a Fc Tag, low endotoxin
CT4-H52A4-structure
CT4-H52A4-sds
CT4-R5250 Rabbit Rabbit CTLA-4 / CD152 Protein, Fc Tag
CT4-R5250-structure
CT4-R5250-sds
CT4-R5259 Rat Rat CTLA-4 / CD152 Protein, Fc Tag
CT4-R5259-structure
CT4-R5259-sds
CT4-M5256 Mouse Mouse CTLA-4 / CD152 Protein, Fc Tag
CT4-M5256-structure
CT4-M5256-sds
CT4-M52H5 Mouse Mouse CTLA-4 / CD152 Protein, His Tag
CT4-M52H5-structure
CT4-M52H5-sds
CT4-H82F3 Human Biotinylated Human CTLA-4 Protein, Fc,Avitag™
CT4-H82F3-structure
CT4-H82F3-sds
CT4-C82E5 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque CTLA-4 Protein, Avitag™,His Tag
CT4-C82E5-structure
CT4-C82E5-sds
CT4-C5227 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CTLA-4 Protein, His Tag (MALS verified)
CT4-C5227-structure
CT4-C5227-sds
CT4-C5256 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CTLA-4 Protein, Fc Tag
CT4-C5256-structure
CT4-C5256-sds
CT4-H5255 Human Human CTLA-4 / CD152 Protein, Fc Tag (MALS verified)
CT4-H5255-structure
CT4-H5255-sds
CT4-H5229 Human Human CTLA-4 / CD152 Protein, His Tag
CT4-H5229-structure
CT4-H5229-sds

Part of Bioactivity data

CT4-H82E3-SPR
Human_FcRn_Heterodimer_Protein_SPR

Biotinylated Human CTLA-4, His,Avitag (Cat. No. CT4-H82E3) captured on Biotin CAP - Series S sensor Chip can bind Yervoy (Ipilimumab) with an affinity constant of 0.635 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

CT4-H5229-SPR
Human_FcRn_Heterodimer_Protein_SPR

Yervoy (Ipilimumab, Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CTLA-4, His Tag (Cat. No. CT4-H5229) with an affinity constant of 25.7 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

CTLA4,CD152

Background

CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that downregulates the immune system. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA-4, an inhibitory receptor for B7 molecules. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ipilimumab Anti-CTLA-4 Mab; 10D1; MDX-010; MDX-101; Mab-10D14; BMS-734016; MDX-CTLA-4 Approved Bristol-Myers Squibb Company Yervoy EU Esophageal Squamous Cell Carcinoma Bristol-Myers Squibb Pharma Eeig 2011-03-25 Sezary Syndrome; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Intraocular Lymphoma; Brain metastases; Neoplasms, Gonadal Tissue; Lung Neoplasms; Carcinoma, Small Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Colorectal Neoplasms; Cholangiocarcinoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Breast Neoplasms; Lymphoma; Waldenstrom Macroglobulinemia; Lymphoma, T-Cell; Lymphoma, Large-Cell, Anaplastic; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Neoplasm Metastasis; Large intestine neoplasm; Adenocarcinoma; Leukemia, Large Granular Lymphocytic; Mycosis Fungoides; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Hodgkin Disease; Liver Neoplasms; Lymphoma, T-Cell, Peripheral; HIV Infections; Kidney Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Ne Details
Cadonilimab AK-104 Approved Zhongshan Akeso Biopharma Co Ltd 开坦尼 Mainland China Uterine Cervical Neoplasms Kangfang Pharmaceutical Co Ltd 2022-06-29 Microsatellite Instability; Melanoma; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; DNA Repair-Deficiency Disorders; Colorectal Neoplasms; Urologic Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Microsatellite instability-high cancer; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Lymphoma, T-Cell, Peripheral Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-CTLA-4 monoclonal antibody (Regeneron) REGN-4659 Phase 1 Clinical Regeneron Pharmaceuticals Inc Carcinoma, Non-Small-Cell Lung Details
Recombinant anti-CTLA-4 human monoclonal antibody (Henlius) Phase 1 Clinical Shanghai Henlius Biotech Co Ltd Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma Details
B7-2/GM-CSF cancer gene therapy CIT Phase 1 Clinical Radient Neoplasms Details
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) Phase 2 Clinical Shanghai Cell Therapy Research Institute Neoplasms Details
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) Phase 2 Clinical Changhai Hospital Of Shanghai Pancreatic Neoplasms Details
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T Phase 2 Clinical Shanghai Cell Therapy Research Institute Solid tumours Details
SKB-337 SKB337; A-337; SKB-337 Phase 1 Clinical Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Solid tumours Details
Recombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering) Phase 2 Clinical Hualan Genetic Engineering Co Ltd Melanoma Details
Ipilimumab biosimilar (Mab-Venture/ShuangLu Pharmaceutical) MV-049 Phase 1 Clinical Beijing Sl Pharmaceutical Co Ltd, Mab-Venture Biopharm Co Ltd Solid tumours Details
Abatacept (Orban Biotech) Phase 2 Clinical Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases Diabetes Mellitus, Type 1 Details
RIVAL-01 TBio-6517; TAK-605 Takeda Pharmaceutical Co Ltd, Turnstone Biologics Inc Details
FPT-155 CD80-Fc; FPT-155 Five Prime Therapeutics Inc Details
BAT-4706 BAT-4706 Phase 1 Clinical Bio-Thera Solutions Ltd Melanoma Details
JS-007 JS-007 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Neoplasms; Lung Neoplasms; Melanoma Details
CD-200-AR-L CD-200-AR-L; hP-1-A-8 Phase 1 Clinical University Of Minnesota Glioblastoma Details
ADG-126 ADG-126 Phase 2 Clinical Adagene Inc Solid tumours Details
RP-3 RP-3 Replimune Inc Details
TWP-102 TWP-102 Phase 1 Clinical Therawisdom Biopharma Co Ltd Neoplasms Details
XTX-101 XTX-101 Details
IMM-27M IMM27M; IMM-27M Phase 1 Clinical Solid tumours Details
ADG-116 ADG-116 Phase 2 Clinical Adagene (Suzhou) Ltd Solid tumours Details
BMS-986249 BMS-986249 Cytomx Therapeutics Details
HBM-4003 HBM-4003 Phase 2 Clinical Harbour Biomed Solid tumours; Neoplasms; Neuroendocrine Tumors; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Ipilimumab biosimilar (Innovent Biologics) IBI-310 Phase 3 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Liver Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms Details
BCD-217 BCD-217 Biocad Details
Nurulimab BCD-145 Biocad Details
Zalifrelimab AGEN-1884; RebmAb-600; UGN-301 Phase 1 Clinical 4-Antibody, Ludwig Institute For Cancer Research Solid tumours; Urinary Bladder Neoplasms Details
ADU-1604 ADU-1604 Aduro Biotech Details
RP-2 RP-2 Replimune, Bristol-Myers Squibb Company Details
ATOR-1015 ADC-1015; ATOR-1015 Alligator Bioscience Details
Bavunalimab XmAb-22841; XmAb-841 Xencor Details
ONCR-177 ONCR-177 Oncorus Details
BA-3071 CAB-CTLA-4; BA-3071 Beigene Ltd, Bioatla Details
Davoceticept ALPN-202 Alpine Immune Sciences Details
Quavonlimab MK-1308; AK-107 Phase 2 Clinical Zhongshan Akeso Biopharma Co Ltd, Merck Sharp & Dohme Corp Solid tumours; Carcinoma, Renal Cell; Neoplasms; Small Cell Lung Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
BT-001 BT-001 Phase 2 Clinical Transgene Solid tumours; Carcinoma, Merkel Cell; Neoplasms; Triple Negative Breast Neoplasms; Sarcoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma Details
MEDI-5752 MEDI-5752 Phase 1 Clinical Medimmune Llc Solid tumours; Carcinoma, Renal Cell Details
IO-102 IO-102 Phase 2 Clinical Herlev Hospital, Merck Sharp & Dohme Corp, Io Biotech Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Squamous Cell; Mouth Neoplasms; Carcinoma, Non-Small-Cell Lung Details
YH-001 YH-001 Phase 2 Clinical Eucure Pharmaceutical Technology (Beijing) Co Ltd Solid tumours; Liver Neoplasms; Neoplasms; Sarcoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Vudalimab XmAb-20717; XmAb-717 Phase 2 Clinical Xencor Vulvar Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Thyroid Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Neuroendocrine; Thymoma; Carcinoma, Squamous Cell; Astrocytoma; Colorectal Neoplasms; Adenocarcinoma, Clear Cell; Cholangiocarcinoma; Prostatic Neoplasms; Solid tumours; Breast Neoplasms; Nasopharyngeal Carcinoma; Adnexal Diseases; Mesothelioma; Adenoma, Acidophil; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Ovarian Neoplasms; Biliary Tract Neoplasms Details
Botensilimab AGEN-1181 Phase 1 Clinical Agenus Inc Ovarian Neoplasms; Solid tumours; Hemangiosarcoma; Neoplasms; Fibrolamellar hepatocellular carcinoma; Endometrial Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
IDO-derived peptide vaccine/PD-L1-derived peptide vaccine IO-102/IO-103 Phase 3 Clinical Herlev Hospital Squamous Cell Carcinoma of Head and Neck; Melanoma Details
Pembrolizumab/Quavonlimab MK-1308A Phase 3 Clinical Merck Sharp & Dohme Corp, Msd Ireland (Carlow), Moshadong R & D (China) Co Ltd Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma Details
Erfonrilimab KN-046; KN046 Phase 3 Clinical Jiangsu Alphamab Biopharmaceuticals Co Ltd, Suzhou Alphamab Co Ltd Solid tumours; Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Thymus Neoplasms; Carcinoma, Pancreatic Ductal; Lymphoma; Thymoma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Lorigerlimab MGD-019; AEX1344 Phase 2 Clinical Macrogenics Liver Neoplasms; Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Melanoma; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
CS-1002 SHR-8068; CS-1002 Phase 2 Clinical Cstone Pharmaceuticals Solid tumours; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
KN-044 KN-044 Phase 1 Clinical Suzhou Alphamab Co Ltd Solid tumours; Neoplasms Details
ONC-392 ONC-392 Phase 2 Clinical Oncoimmune Carcinoma, Adenoid Cystic; Adenocarcinoma; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Breast Neoplasms; Sarcoma; Prostatic Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Salivary Gland Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Renal Cell; Esophageal Neoplasms; Cystadenocarcinoma, Serous; Stomach Neoplasms; Solid tumours; Head and Neck Neoplasms Details
Iparomlimab/Tuvonralimab QL-1706; PSB-205; PBS-103/PBS-105 Phase 3 Clinical Qilu Pharmaceutical Co Ltd Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Neoplasms; Colorectal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
SI-B003 SI-B003 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message